Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2040622316659863 http://scihub22266oqcxt.onion/10.1177/2040622316659863 C5076744!5076744!27803792     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ther+Adv+Chronic+Dis 2016 ; 7 (6): 260-77 Nephropedia Template TP {{tp|p=27803792|t=2016. Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential |pdf=|usr=}}{{27803792}} gab.com Text Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential JO: Ther Adv Chronic Dis http://www.kidney.de/pget.php?&tw=1&pmid=27803792 #FOAvip Severe asthma is characterized by major impairment of quality of life, poor symptom control and frequent exacerbations. Inflammatory, clinical and causative factors identify different phenotypes and endotypes of asthma. In the last few years, new treatment options have allowed for targeted treatments according to the different phenotypes of the disease. To accurately select a specific treatment for each asthmatic variant, the identification of appropriate biomarkers is required. Eosinophilic asthma is a distinct phenotype characterized by thickening of the basement membrane and corticosteroid responsiveness. This review reports the latest evidence on an anti-IL-5 monoclonal antibody, mepolizumab, a new and promising biological agent recently approved by the FDA specifically for the treatment of severe eosinophilic refractory asthma. Twit Text FOAVip Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential ????Ther Adv Chronic Dis http://www.kidney.de/pget.php?&tw=1&pmid=27803792 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27803792 #FOAvip English Wikipedia <ref>{{Cite pmid|27803792}}</ref> Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential #MMPMID27803792 Menzella F; Lusuardi M; Galeone C; Taddei S; Facciolongo N; Zucchi L Ther Adv Chronic Dis 2016[Nov]; 7 (6): 260-77 PMID27803792show ga Severe asthma is characterized by major impairment of quality of life, poor symptom control and frequent exacerbations. Inflammatory, clinical and causative factors identify different phenotypes and endotypes of asthma. In the last few years, new treatment options have allowed for targeted treatments according to the different phenotypes of the disease. To accurately select a specific treatment for each asthmatic variant, the identification of appropriate biomarkers is required. Eosinophilic asthma is a distinct phenotype characterized by thickening of the basement membrane and corticosteroid responsiveness. This review reports the latest evidence on an anti-IL-5 monoclonal antibody, mepolizumab, a new and promising biological agent recently approved by the FDA specifically for the treatment of severe eosinophilic refractory asthma. äMepolizumab for severe refractory eosinophilic asthma: evidence to dat(epmc).pdf DeepDyve Pubget Overpricing